<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/C49C66E3-8EF1-43E8-82A1-7A8347F84C2B"><gtr:id>C49C66E3-8EF1-43E8-82A1-7A8347F84C2B</gtr:id><gtr:name>Sentinel Oncology Limited</gtr:name><gtr:address><gtr:line1>SUITE 52 23 SCIENCE PARK , MILTON ROAD</gtr:line1><gtr:city>CAMBRIDGE</gtr:city><gtr:postCode>CB4 0EY</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C49C66E3-8EF1-43E8-82A1-7A8347F84C2B" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>C49C66E3-8EF1-43E8-82A1-7A8347F84C2B</gtr:id><gtr:name>Sentinel Oncology Limited</gtr:name><gtr:address><gtr:line1>SUITE 52 23 SCIENCE PARK , MILTON ROAD</gtr:line1><gtr:city>CAMBRIDGE</gtr:city><gtr:postCode>CB4 0EY</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>965633.0</gtr:offerGrant><gtr:projectCost>1609388.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/4DCE9BB9-7EC4-4634-8E84-BC5B95DD5523"><gtr:id>4DCE9BB9-7EC4-4634-8E84-BC5B95DD5523</gtr:id><gtr:firstName>Stuart</gtr:firstName><gtr:surname>Travers</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=102422"><gtr:id>C6A49747-F30C-4CD8-BFA6-9F4C4B777A25</gtr:id><gtr:title>Development of a new drug for the treatment of Autism caused by Fragile X Syndrome</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Collaborative R&amp;D</gtr:grantCategory><gtr:grantReference>102422</gtr:grantReference><gtr:abstractText>Fragile X Syndrome is the single largest cause of genetically inherited disability amongst diseases

categorised within the autism spectrum disorders.

This proposal will aim to develop a new treatment for Fragile X syndrome, called SOL101, which will

treat the underlying cause of the disease rather than the symptoms. SOL101 has already demonstrated

proof of concept in pre-clinical disease models and the proposal will develop it to the start of clinical

trials.

As well as the healthcare benefits to the patiens, in terms of alleviation of symptoms, both neurological

and physical, the cost savings in terms of reduced needs for ongoing care and education assistance will

be considerable.

Finance summary table</gtr:abstractText><gtr:fund><gtr:end>2017-10-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2015-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>965633</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">102422</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>